Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients

摘要: Purpose: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates broad antitumor response. We report on the results of phase II trial in which patients underwent vaccination following stem cell transplantation (ASCT) to target minimal residual disease. Experimental Design: Twenty-four received serial vaccinations cell/myeloma fusion posttransplant hematopoietic recovery. second cohort 12 pretransplant followed by vaccinations. Dendritic generated from adherent mononuclear cultured granulocyte macrophage colony-stimulating factor, interleukin-4, and TNF-α were bone marrow–derived using polyethylene glycol. Fusion quantified determining percentage coexpress antigens. Results: The period was associated reduction general measures cellular immunity; however, an increase CD4 CD8 + myeloma-specific T observed after ASCT significantly expanded vaccination. Seventy-eight percent achieved best response complete (CR)+very good partial (VGPR) 47% CR/near CR (nCR). Remarkably, 24% who transplant converted CR/nCR at more than 3 months posttransplant, consistent vaccine-mediated effect Conclusions: for provides unique platform immunotherapy fusions resulted marked expansion cytoreduction Clin Cancer Res; 19(13); 3640–8. ©2013 AACR .